Barclays analyst Andrew Mok raised the firm’s price target on Privia Health (PRVA) to $21 from $19 and keeps an Equal Weight rating on the shares post the Q3 report. Privia showed steady progress with modest outperformance in multiple books of business enabling a free cash flow raise, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health Group Reports Strong Q3 2024 Results
- Privia Health reports Q3 adjusted EPS 20c, consensus 5c
- Privia Health raises 2024 revenue view to high end of $1.60B-$1.675B view
- Humana or Privia: KeyBanc Selects the Superior Healthcare Service Stock to Buy
- Privia Health initiated with an Overweight at KeyBanc